 NantKwest, Inc. Nasdaq: NK, a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBios COVID-19 human adenovirus vaccine hAd5 candidate. This is the first vaccine designed to deliver both Spike S and Nucleocapsid N DNA, offering the potential for patients to develop long-lasting immunity to the virus. 